25 April 2013  
EMA/246157/2013  
Human Medicines Development and Evaluation 
Statement indicating  compliance with the agreed completed 
paediatric investigation plan 
Medicinal product 
Menveo 
MENINGOCOCCAL GROUP A, C, W135 AND Y CONJUGATE VACCINE 
Pharmaceutical form: 
See Annex A of the CHMP Opinion 
Strengths: 
See Annex A of the CHMP Opinion 
Route of administration: 
See Annex A of the CHMP Opinion 
Packaging and package sizes: 
See Annex A of the CHMP Opinion 
Numbers in the Community 
See Annex A of the CHMP Opinion 
Register of Medicinal Products: 
Marketing Authorisation Holder (MAH): 
Name and address of the MAH:  Novartis Vaccines and Diagnostics S.r.l. 
Via Fiorentina, 1 
IT-53100 Siena 
Italy 
Procedure 
Procedure number: 
EMEA/H/C/001095/II/0018 
Further to the compliance check performed under Article 23 of Regulation (EC) No 1901/2006, and in 
accordance with Article 28(3) and Article 45(3) of the said Regulation it is concluded that: 
• 
• 
the development of this product has complied with all measures in the agreed paediatric 
investigation plan P/93/2011. For the purpose of the application of Article 45(3) of Regulation EC 
(No) 1901/2006, significant studies in the agreed paediatric investigation plan P/93/2011 have 
been completed after the entry into force of that Regulation, 
the Summary of Product Characteristics adopted by CHMP reflects the results of studies conducted 
in compliance with this agreed paediatric investigation plan. 
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom 
Telephone  +44 (0)20 3660 6000  Facsimile +44 (0)20 3660 5555 
Send a question via our website www.ema.europa.eu/contact 
An agency of the European Union   
© European Medicines Agency, 2015. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
  
 
  
 
 
 
